Detalhe da pesquisa
1.
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Ann Oncol
; 35(3): 267-275, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38145866
2.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Ann Oncol
; 33(11): 1149-1158, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35961599
3.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Ann Oncol
; 32(10): 1245-1255, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224826
4.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol
; 32(8): 983-993, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272041
5.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Ann Oncol
; 32(8): 994-1004, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34219000
6.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Ann Oncol
; 32(12): 1590-1596, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34520831
7.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapyâ.
Ann Oncol
; 32(4): 500-511, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33418062
8.
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Ann Oncol
; 32(1): 49-57, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098995
9.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Ann Oncol
; 31(5): 582-589, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32178964
10.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Ann Oncol
; 31(9): 1216-1222, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461104
11.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Ann Oncol
; 30(5): 766-773, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796821
12.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol
; 30(8): 1279-1288, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31095287
13.
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Ann Oncol
; 29(1): 178-185, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29069370
14.
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Ann Oncol
; 29(8): 1763-1770, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29878040
15.
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Ann Oncol
; 29(12): 2341-2347, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30335131
16.
[Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies]. / Spinale Mammakarzinommetastasen aus Sicht der Wirbelsäulenchirurgie : Prädiktoren auf Molekularebene zur Wahl der adäquaten Therapiestrategie.
Orthopade
; 47(7): 594-603, 2018 07.
Artigo
em Alemão
| MEDLINE | ID: mdl-29487982
17.
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Ann Oncol
; 28(4): 761-768, 2017 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057664
18.
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Ann Oncol
; 28(8): 1803-1810, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28459941
19.
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Ann Oncol
; 28(4): 754-760, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993816
20.
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Ann Oncol
; 33(7): 743-744, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595658